ESMO: Novel Checkpoint Inhibitors From Merck And BMS Show Promise
Patients Progressing On PD-1/PD-L1s Need Options
TIGIT is not the only novel IO mechanism showing promise, with market leaders Merck and BMS showcasing data from other early stage combinations with Opdivo and Keytruda, while Servier presented a possible three-way combo.
You may also be interested in...
Data show better safety than Opdivo/Yervoy, though what appears to be slightly lower efficacy, in first-line metastatic or unresectable melanoma.
LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.